Application of the Transmembrane Therapeutic Protein Production Platform (TTPPP) to an innovative approach for the Treatment of Cancer or Immunosuppression
Application of the platform of production of transmembrane therapeutic proteins (PPTTP) to an innovative approach to the treatment of cancer of immunosuppression
The aim of the project is to develop new cancer or immunosuppressive treatments by designing and developing an innovative process for the production of transmembrane death proteins, inserted in natural lipid nanovesicles, as the active principle of such treatment.
To this end, a consortium has been set up, consisting of Thrombotargets Europe, S.L. And the Health & Biomedicine Unit of the Leitat Technology Center, combining the biotechnological knowledge owned by Thrombotargets, necessary to obtain transmembrane proteins to produce programmed cell death with increased potency and bioselectivity, and the extensive preclinical and clinical experience accumulated by Leitat In areas such as oncology, in charge of studying new methodologies applied to the fight against cancer and autoimmune diseases.
The complementarity of both entities, together with a common translational objective, will allow for the launch of new products with high demand due to the sample size of the population suffering from cancer-related diseases and autoimmune disorders.
Project Budget: 804’574,14 €
Financial Framework: RETOS COLABORACIÓN
Contract number: RTC-2016-5484-1
Start Date: 05/03/2016
End Date: 31/12/2019
The project TTPPP, with file number RTC-2016-5484-1, approved in the 2016 Call for the State Program of R + D + i, oriented to the Challenges of the Society, has been financed by the Ministry of Economy, Industry and Competitiveness and co-financed through European Union FEDER funds with the main objective of Promoting technological development, innovation and quality research.